Early initiation of antiretroviral therapy and universal HIV testing in sub-Saharan Africa: Has WHO offered a milestone for HIV prevention

Journal of Public Health Policy

Volumn 31, Issue 4, 2010, Pages 385-400

  Menon, Sonia ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

early ART initiation; HIV; sub Saharan Africa; universal testing

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ARTICLE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DISEASE TRANSMISSION; ECONOMICS; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PUBLIC HEALTH; RISK FACTOR; TIME; UTILIZATION REVIEW; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEALTH RESOURCES; HEALTH SERVICES; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH; RISK FACTORS; TIME FACTORS; WORLD HEALTH ORGANIZATION;

EID: 78649831898     PISSN: 01975897     EISSN: 1745655X     Source Type: Journal    
DOI: 10.1057/jphp.2010.29     Document Type: Article

References (36)

1. Granich, R. et al (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. The Lancet 373(9657): 48-57.
2. WHO. (2009) New HIV recommendations to improve health, reduce infections and save lives, http://www.who.int/mediacentre/news/releases/2009/world-aids- 20091130/en/index.html, accessed 20 July 2010.
3. Hughes, R., Sabin, C. and Sterne, J. (2007) Long-term trends in CD4 count in patients starting HAART: UK-CHIC study [Abstract P18.4/04]. 11th European AIDS Conference, Madrid, http://www.aidsmeds.com/articles/hiv-cd4-uk-2094-13356. shtml, accessed 25 October 2009.
4. May, M. et al (2007) Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS 21(9): 1185-1197.
5. Lori, F. et al (1999) Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. Journal of Infectious Diseases 180(6): 1827-1832.
6. Rosenberg, E.S. et al (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407(6803): 523-526.
7. Oxenius, A. et al (2000) Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proceedings National Academy of Science of USA, 28 March 2000; 97(7), pp. 3382-3387. http://www.ncbi.nlm.nih.gov/pubmed/10737796, accessed 25 October 2009.
8. Malhotra, U. et al (2000) Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 181(1): 121-131.
9. Gottlieb, G.S. (2003) Early HIV-1 viral diversity associated with rapid disease progression. NLM Gateway Abstract 10th Conference Retroviral Opportunistic Infections Feb 10 http://gateway.nlm.nih.gov/MeetingAbstracts/ma? f=102261104.html, accessed 1 November 2009.
10. Selwyn, P.A., Hartel, D. and Lewis, V.A. et al (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New England Journal of Medicine 320: 545-550.
11. Schluger, N.W. and Rom, W.N. (1998) The host immune response to tuberculosis. American Journal of Respiratory and Critical Care Medicine 157(3): 679-691.
12. Quinn, T.C. et al (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 342(13): 921-929.
13. Modjarrad, K. and Vermund, S.H. (2010) Effect of treating co-infections on HIV-1 viral load: A systematic review. The Lancet Infectious Diseases 10(7): 455-463.
14. Moh, R. (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21(18): 2483-2491.
15. USAID Tanzania. (2008) http://www.usaid.gov/our-work/global-health/id/ tuberculosis/countries/africa/tanzania-profile.htm, accessed 25 October 2009.
16. Carpenter, C.C., Fischl, M.A. and Hammer, S.M. et al (1996) Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. Journal of the American Medical Association 276(2): 146-154.
17. Richman, D.D., Morton, S.C. and Wrin, T. et al (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18(10): 1393-1401.
18. Paterson, D.L., Swindells, S. and Mohr, J. et al (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133(1): 21-30.
19. Carr, A., Samaras, K. and Burton, S. et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7): F51-F58.
20. AIDS Info. (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, = Guideline, accessed 25 October 2009.
21. Hammer, S.M., Eron Jr, J.J. and Reiss, P. et al (2008) Antiretroviral treatment of dult HIV infection: 2008 Recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 300(5): 555-570.
22. Sax, P.E. and Baden, L.R. (2009) When to start antiretroviral therapy - Ready when you are? New England Journal of Medicine 360(18): 1897-1899.
23. Walensky, R.P. andWolf, L.L. et al (2009) When to start antiretroviral therapy in resourcepoor settings. Annals of Internal Medicine 151(3): 157-166.
24. Shelburne, S.A., Montes, M. and Hamill, R.J. (2006) Immune reconstitution inflammatory syndrome: More answers, more questions. Journal of Antimicrobial Chemotherapy 57(2): 167-170.
25. CDC NIH HIVMA/IDSA. (2008) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, http://www.aidsinfo.nih.gov/contentfiles/Adult-OI000999.pdf, accessed 12 December 2009.
26. Badri, M., Lawn, S. and Wood, R. (2008) Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infectious Diseases 8: 89.
27. Bio Medicine. (2005) Drug resistance testing in treatment naive HIV is cost effective, http://news.bio-medicine.org/medicine-news-3/Drug-resistance- testing-in-treatment-nave-HIV-patients-is-cost-effective-8520-1, accessed 17 November 2009.
28. El-Sadr, W.M. and Lundgren, J.D. et al (2006) The strategies for management of ART therapy (SMART) study group. CDR+ count-guided interruption of antiretroviral, http://www.nejm.org/doi/pdf/10.1056/NEJMoa062360, accessed 2 February 2009.
29. AMREF UK. (2009) HIV voluntary counselling and testing. Tanzania: http://uk.amref.org/what-we-do/hiv-voluntary-counselling-and-testing-tanzania, accessed 7 February 2009.
30. Tanzania Commission for HIV/AIDS. (2003) National multi-sectoral strategic framework on HIV/AIDS framework on HIV/AIDS 2003-2007 http://www.tanzania.go.tz/pdf/tacaidsnmf.pdf, accessed 6 February 6, 2009.
31. Asante, A.D. (2007) Scaling up HIV prevention: Why routine or mandatory testing is not feasible for sub-Saharan Africa. Bulletin World Health Organization 85(8): 644-646.
32. Leach-Lemens, C. and Owuor, J. (2009) Scaling up HIV testing and counselling towards universal access: what works in resource-limited settings? AIDSMAP http://www.aidsmap.com/cms1330557.aspx, accessed 2 February 2010.
33. Roura, M., Urassa, M., Bsza, J., Mbata, D., Wringe, A. and Zaba, B. (2008) Scaling up stigma? The effects of ART roll-out on stigma and HIV testing. Early evidence from rural Tanzania. Sexually Transmitted Infections 85(4): 308-312.
34. McNeil, D.G. (2010) At front lines, AIDS war is falling apart. New York Times, 9 May.
35. De Cock, K.M. et al (2003) A serostatus approach to HIV/AIDS prevention and care in Africa. The Lancet 362: 1847-1849.
36. Garnett, G. and Baggeley, R.F. (2008) Treating our way out of the HIV pandemic: Could we, would we, should we? The Lancet 373(2009): 9-11.